PD Dr. Robin Niklas Reschke is Max-Eder Group Leader at University Hospital Heidelberg & NCT & DKFZ, where he leads a group focused on tumor immunology. His research bridges dermatology, cancer immunology, and precision oncology, with a focus on skin cancer progression and immune-related adverse events in immunotherapy. Using spatial transcriptomics, single-cell RNA/TCR sequencing, and high-plex proteomics, his team maps the tumor–immune interface to discover biomarkers and develop personalized treatments. As a dermatologist and translational scientist, he is passionate about bringing cutting-edge science to the clinic, mentoring young researchers, and building international collaborations.